CD274 and neoplasm: Currently, several clinical studies evaluating PD-1/PD-L1 inhibitors have been conducted in several different tumor types including breast, colorectal, anal, gastric, renal cell carcinoma, head, and neck, pancreatic, and hepatocellular cancer.